With its Research and Development sites located in different continents worldwide, Ceva is committed to develop innovative vaccines that can meet the current needs; to ensure small ruminants’ health...

Ceva’s background and continuous work in biological products provides excellency in the prevention of small ruminants’ diseases:

  • COGLAVAX® / COGLAVAX® S (clostridiosis): vaccines containing several clostridial antigens in one single dose. Clostridial pathogens are ubiquitous and small ruminants are at risk to be hit by these diseases during most part of their lives.
  • COXEVAC® (coxiellosis or Q fever): a vaccine to protect against Q fever. This disease causes significant reproductive losses in both cattle and small ruminants. Moreover, it is a zoonosis therefore humans can be infected and suffer from the disease too. It has the advantage of being a so-called "phase 1" vaccine which, when used for prevention, not only minimizes the disease’s clinical impact, but also considerably reduces or even eliminates bacteria excretion in vaccinated animals, thereby limiting contamination of the external environment.
  • CEVAC CHLAMYDOPHILA® (chlamydiosis): a live vaccine to protect sheep and goats against enzootic abortion induced by Chlamydophila abortus. A single administration of the females prior to breeding has been proven to reduce abortion and shedding for a long period of time (3 years).


From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top